论文部分内容阅读
【目的】探讨 FOLFOX4化疗方案联合西妥昔单抗治疗转移性结肠癌的临床疗效及其作用机制。【方法】将65例转移性结肠癌患者随机分为观察组（33例）和对照组（32例）；对照组给予 FOLFOX4化疗方案治疗，观察组在对照组的化疗方案上联合西妥昔单抗治疗；观察两组患者治疗后的有效性和安全性，并检测治疗前后患者血清中胰岛素样生长因子‐1（IGF‐1）、血管内皮生长因子（VEGF）的水平变化。【结果】观察组患者的有效率为66．67％，明显高于对照组的46．88％，差异有统计学意义（ P＜0．05）；两组患者治疗后血清IG F‐1、V EG F水平均明显降低，与治疗前比较差异有统计学意义（P ＜0．05），且观察组优于对照组（P ＜0．05）；两组不良发应比较无统计学差异（ P ＞0．05）。【结论】FOLFOX4化疗方案联合西妥昔单抗治疗转移性结肠癌疗效显著，通过调节血清中IG F‐1、V EG F水平变化可能是其作用机制之一。“,”[Objective] To explore the clinical efficacies and mechanism of FOLFOX4 chemotherapy plus cetuximab for metastatic colorectal cancer (MCC) .[Methods]A total of 65 MCC patients were randomly divided into observation ( n=33) and control ( n=32) groups .The control group received FOLFOX4 chemotherapy .And the observation had ad‐ditional cetuximab treatment .After treatment ,the efficacy and safety were compared for two groups .And the serum lev‐els of insulin‐like growth factor‐1 (IGF‐1) and vascular endothelial growth factor (VEGF) were recorded before and after treatment .[Results] The effective rate was significantly higher in observation group than that in control group (66 .67%vs 46 .88% ,P<0 .05) .In both groups ,the serum levels of IGF‐1 and VEGF declined significantly after treatment .And the differences were statistically significant compared with before treatment ( P<0 .05) .And observation group was bet‐ter than control group ( P0 .05) .[Con‐clusion] FOLFOX4 chemotherapy plus cetuximab is markedly efficacious for MCC .And modulating the serum levels of IGF‐1 and VEGF changes may be one of its mechanisms .